Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 4/2012

01.05.2012

Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention

verfasst von: Alessandro Lupi, Gioel Gabrio Secco, Andrea Rognoni, Lidia Rossi, Maurizio Lazzero, Federico Nardi, Roberta Rolla, Giorgio Bellomo, Angelo Sante Bongo, Carlo Di Mario

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Plasma fibrinogen levels influence restenosis following elective percutaneous coronary intervention (PCI) for stable angina. It is unknown whether the same is true in the setting of primary PCI. The aim of the study was therefore to assess whether fibrinogen levels were associated to 6-month in-stent restenosis (ISR) in STEMI patients undergoing successful primary PCI. From January 2003 to October 2004, 267 patients were admitted to our Institution for STEMI and treated by primary PCI. Of these, 171 patients met the inclusion criteria and were enrolled in our study. Fibrinogen levels were assessed at admission, 12 h, 24 h, 48 h, 72 h following PCI and at discharge. Six-month angiographic follow-up was 100% complete. Subjects with 6-month ISR showed higher fibrinogen levels than patients without ISR. Patients in the upper fibrinogen tertile showed a higher 6-month incidence of symptoms and/or inducible myocardial ischemia (27.1% vs. 7.1%, P = 0.006) and a larger late lumen loss (1.3 ± 0.8 vs. 1.0 ± 0.9 mm, P = 0.049). Logistic regression analysis demonstrated a significant and independent association between fibrinogen levels and ISR. Our study suggests that increased plasma fibrinogen levels are related to ISR in STEMI patients undergoing primary PCI. Larger studies are warranted to assess the prognostic value of fibrinogen over harder end-points.
Literatur
1.
Zurück zum Zitat Meade TW, Mellows S, Bronzovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG (1986) Hemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533–537PubMedCrossRef Meade TW, Mellows S, Bronzovic M, Miller GJ, Chakrabarti RR, North WRS, Haines AP, Stirling Y, Imeson JD, Thompson SG (1986) Hemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533–537PubMedCrossRef
2.
Zurück zum Zitat Kannel WB, Wolf PA, Castelli WP, D’Agostino RB (1987) Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 258:1183–1186PubMedCrossRef Kannel WB, Wolf PA, Castelli WP, D’Agostino RB (1987) Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA 258:1183–1186PubMedCrossRef
3.
Zurück zum Zitat Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501–505PubMedCrossRef Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G (1984) Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311:501–505PubMedCrossRef
4.
Zurück zum Zitat Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC (1991) Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell collaborative heart disease studies. Circulation 83:836–844PubMed Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O’Brien JR, Whitehead PJ, Elwood PC (1991) Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease: the Caerphilly and Speedwell collaborative heart disease studies. Circulation 83:836–844PubMed
5.
Zurück zum Zitat ECAT angina pectoris study group (1993) ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 14:8–17CrossRef ECAT angina pectoris study group (1993) ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 14:8–17CrossRef
6.
Zurück zum Zitat Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB (1990) Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 85:169–173PubMedCrossRef Broadhurst P, Kelleher C, Hughes L, Imeson JD, Raftery EB (1990) Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 85:169–173PubMedCrossRef
7.
Zurück zum Zitat Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K (1997) Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 17:3208–3214PubMedCrossRef Tschopl M, Tsakiris DA, Marbet GA, Labs KH, Jager K (1997) Role of hemostatic risk factors for restenosis in peripheral arterial occlusive disease after transluminal angioplasty. Arterioscler Thromb Vasc Biol 17:3208–3214PubMedCrossRef
8.
Zurück zum Zitat Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D (1995) Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 92:31–38PubMed Montalescot G, Ankri A, Vicaut E, Drobinski G, Grosgogeat Y, Thomas D (1995) Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation 92:31–38PubMed
9.
Zurück zum Zitat Rahel M, Visseren FLJ, Suttorp MJ, Plokker THW, Kelder JC, de Jongh BM, Bouter KP, Diepersloot RJA (2003) Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res 60:136–140PubMedCrossRef Rahel M, Visseren FLJ, Suttorp MJ, Plokker THW, Kelder JC, de Jongh BM, Bouter KP, Diepersloot RJA (2003) Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res 60:136–140PubMedCrossRef
10.
Zurück zum Zitat Otsuka M, Hayashi Y, Ueda H, Imazu M, Kohno N (2002) Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis 164:371–378PubMedCrossRef Otsuka M, Hayashi Y, Ueda H, Imazu M, Kohno N (2002) Predictive value of preprocedural fibrinogen concerning coronary stenting. Atherosclerosis 164:371–378PubMedCrossRef
11.
Zurück zum Zitat Shammas NW, Shammas G, Bryan D, Rauba J, Dippel E, Jerin M (2009) Predictors of target lesion revascularization in patients undergoing lower extremity percutaneous interventions. J Invasive Cardiol 21:266–269PubMed Shammas NW, Shammas G, Bryan D, Rauba J, Dippel E, Jerin M (2009) Predictors of target lesion revascularization in patients undergoing lower extremity percutaneous interventions. J Invasive Cardiol 21:266–269PubMed
12.
Zurück zum Zitat Wahlgren CM, Sten-Linder M, Egberg N, Kalin B, Blohmé L, Swedenborg J (2006) The role of coagulation and inflammation after angioplasty in patients with peripheral arterial disease. Cardiovasc Intervent Radiol 29:530–535PubMedCrossRef Wahlgren CM, Sten-Linder M, Egberg N, Kalin B, Blohmé L, Swedenborg J (2006) The role of coagulation and inflammation after angioplasty in patients with peripheral arterial disease. Cardiovasc Intervent Radiol 29:530–535PubMedCrossRef
13.
Zurück zum Zitat Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel EP, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N (2007) Universal definition of myocardial infarction. Circulation 116:2634–2653.
14.
Zurück zum Zitat Clauss A (1957) Gerinnungsphysiologishe Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17:237–246PubMedCrossRef Clauss A (1957) Gerinnungsphysiologishe Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 17:237–246PubMedCrossRef
15.
Zurück zum Zitat Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, for the Academic Research Consortium (2007) Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, for the Academic Research Consortium (2007) Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation 115:2344–2351PubMedCrossRef
16.
Zurück zum Zitat Rits IA (1964) Declaration of Helsinki. Recommendations guidings doctors in clinical research. World Med J 11:281PubMed Rits IA (1964) Declaration of Helsinki. Recommendations guidings doctors in clinical research. World Med J 11:281PubMed
17.
Zurück zum Zitat Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D’Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Piñango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssönen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Després JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis (Fibrinogen Studies Collaboration). JAMA 294:1799–1809PubMedCrossRef Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M, Goldbourt U, Willeit J, Kiechl S, Yarnell JW, Sweetnam PM, Elwood PC, Cushman M, Psaty BM, Tracy RP, Tybjaerg-Hansen A, Haverkate F, de Maat MP, Fowkes FG, Lee AJ, Smith FB, Salomaa V, Harald K, Rasi R, Vahtera E, Jousilahti P, Pekkanen J, D’Agostino R, Kannel WB, Wilson PW, Tofler G, Arocha-Piñango CL, Rodriguez-Larralde A, Nagy E, Mijares M, Espinosa R, Rodriquez-Roa E, Ryder E, Diez-Ewald MP, Campos G, Fernandez V, Torres E, Marchioli R, Valagussa F, Rosengren A, Wilhelmsen L, Lappas G, Eriksson H, Cremer P, Nagel D, Curb JD, Rodriguez B, Yano K, Salonen JT, Nyyssönen K, Tuomainen TP, Hedblad B, Lind P, Loewel H, Koenig W, Meade TW, Cooper JA, De Stavola B, Knottenbelt C, Miller GJ, Cooper JA, Bauer KA, Rosenberg RD, Sato S, Kitamura A, Naito Y, Palosuo T, Ducimetiere P, Amouyel P, Arveiler D, Evans AE, Ferrieres J, Juhan-Vague I, Bingham A, Schulte H, Assmann G, Cantin B, Lamarche B, Després JP, Dagenais GR, Tunstall-Pedoe H, Woodward M, Ben-Shlomo Y, Davey Smith G, Palmieri V, Yeh JL, Rudnicka A, Ridker P, Rodeghiero F, Tosetto A, Shepherd J, Ford I, Robertson M, Brunner E, Shipley M, Feskens EJ, Kromhout D, Dickinson A, Ireland B, Juzwishin K, Kaptoge S, Lewington S, Memon A, Sarwar N, Walker M, Wheeler J, White I, Wood A (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis (Fibrinogen Studies Collaboration). JAMA 294:1799–1809PubMedCrossRef
18.
Zurück zum Zitat Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118:956–963PubMed Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118:956–963PubMed
19.
Zurück zum Zitat Fibrinogen Studies Collaboration (2004) Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil 11:9–17 Fibrinogen Studies Collaboration (2004) Collaborative meta-analysis of prospective studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil 11:9–17
20.
Zurück zum Zitat Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, Hiroki T, Arakawa K (1989) Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 77:209–213PubMedCrossRef Handa K, Kono S, Saku K, Sasaki J, Kawano T, Sasaki Y, Hiroki T, Arakawa K (1989) Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis. Atherosclerosis 77:209–213PubMedCrossRef
21.
Zurück zum Zitat Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V (1988) Platelet thrombus formation on collagen type I: a model of deep vessel injury: influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation 78:1431–1442PubMedCrossRef Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V (1988) Platelet thrombus formation on collagen type I: a model of deep vessel injury: influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation 78:1431–1442PubMedCrossRef
22.
Zurück zum Zitat Harker LA (1987) Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 60:20B–28BPubMedCrossRef Harker LA (1987) Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 60:20B–28BPubMedCrossRef
23.
Zurück zum Zitat Ip JH, Fuster V, Badimon L, Badimon JJ, Taubman MB, Chesebro JH (1990) Syndromes of accelerated atherosclerosis: role of vascular injury and smooth cell proliferation. J Am Coll Cardiol 15:1667–1687PubMedCrossRef Ip JH, Fuster V, Badimon L, Badimon JJ, Taubman MB, Chesebro JH (1990) Syndromes of accelerated atherosclerosis: role of vascular injury and smooth cell proliferation. J Am Coll Cardiol 15:1667–1687PubMedCrossRef
24.
Zurück zum Zitat Shah PK, Amin J (1992) Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 85:1279–1285PubMed Shah PK, Amin J (1992) Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty. Circulation 85:1279–1285PubMed
25.
Zurück zum Zitat Schumacher M, Eber B, Tiran A, Toplak H, Luha O, Gasser R, Klein W (1992) Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angioplasty. Cardiology 80:345–348PubMedCrossRef Schumacher M, Eber B, Tiran A, Toplak H, Luha O, Gasser R, Klein W (1992) Fibrinogen values in patients with and without restenosis following percutaneous transluminal coronary angioplasty. Cardiology 80:345–348PubMedCrossRef
26.
Zurück zum Zitat Naito M, Stirk C, Smith E, Thompson W (2000) Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin E in restenosis and atherogenesis. Thromb Res 98:165–174PubMedCrossRef Naito M, Stirk C, Smith E, Thompson W (2000) Smooth muscle cell outgrowth stimulated by fibrin degradation products. The potential role of fibrin E in restenosis and atherogenesis. Thromb Res 98:165–174PubMedCrossRef
27.
Zurück zum Zitat Jaster M, Horstkotte D, Willich T, Stellbaum C, Knie W, Spencker S, Pauschinger M, Schultheiss HP, Rauch U (2008) The amount of fibrinogen-positive platelets predicts the occurrence of in-stent restenosis. Atherosclerosis 197:190–196PubMedCrossRef Jaster M, Horstkotte D, Willich T, Stellbaum C, Knie W, Spencker S, Pauschinger M, Schultheiss HP, Rauch U (2008) The amount of fibrinogen-positive platelets predicts the occurrence of in-stent restenosis. Atherosclerosis 197:190–196PubMedCrossRef
28.
Zurück zum Zitat Kamath S, Lip GY (2003) Fibrinogen: biochemistry, epidemiology and determinants. QJM 96:711–729PubMedCrossRef Kamath S, Lip GY (2003) Fibrinogen: biochemistry, epidemiology and determinants. QJM 96:711–729PubMedCrossRef
29.
Zurück zum Zitat Rosenson RS (1993) Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22:933–940PubMedCrossRef Rosenson RS (1993) Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22:933–940PubMedCrossRef
30.
31.
Zurück zum Zitat The Fibrinogen Studies Collaboration (2007) Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154, 211 adults in 31 prospective studies. Am J Epidemiol 166:867–879CrossRef The Fibrinogen Studies Collaboration (2007) Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154, 211 adults in 31 prospective studies. Am J Epidemiol 166:867–879CrossRef
32.
Zurück zum Zitat Ørn S, Manhenke C, Ueland T, Damås JK, Mollnes TE, Edvardsen T, Aukrust P, Dickstein K (2009) C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 30:1180–1186PubMedCrossRef Ørn S, Manhenke C, Ueland T, Damås JK, Mollnes TE, Edvardsen T, Aukrust P, Dickstein K (2009) C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 30:1180–1186PubMedCrossRef
33.
Zurück zum Zitat Harjai KJ, Grines C, Stone GW, Boura J, Turco M, Brodie B, Sadeghi HM, Cox D, Grines L, O’ Neill WW (2003) Frequency, determinants, and clinical implications of residual intracoronary thrombus following primary angioplasty for acute myocardial infarction. Am J Cardiol 92:377–382PubMedCrossRef Harjai KJ, Grines C, Stone GW, Boura J, Turco M, Brodie B, Sadeghi HM, Cox D, Grines L, O’ Neill WW (2003) Frequency, determinants, and clinical implications of residual intracoronary thrombus following primary angioplasty for acute myocardial infarction. Am J Cardiol 92:377–382PubMedCrossRef
34.
Zurück zum Zitat Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A (1999) Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34:1512–1521PubMedCrossRef Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, Crea F, Maseri A (1999) Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 34:1512–1521PubMedCrossRef
35.
Zurück zum Zitat Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, Trani C, Rebuzzi AG, Crea F (2008) Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med 9:156–165PubMedCrossRef Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, Trani C, Rebuzzi AG, Crea F (2008) Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med 9:156–165PubMedCrossRef
36.
Zurück zum Zitat Ferns GA, Avades TY (2000) The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 81:63–88PubMedCrossRef Ferns GA, Avades TY (2000) The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 81:63–88PubMedCrossRef
37.
Zurück zum Zitat Hoffmann R, Mintz GS (2000) Coronary in-stent restenosis: predictors, treatment and prevention. Eur Heart J 21:1739–1749PubMedCrossRef Hoffmann R, Mintz GS (2000) Coronary in-stent restenosis: predictors, treatment and prevention. Eur Heart J 21:1739–1749PubMedCrossRef
Metadaten
Titel
Plasma fibrinogen levels and restenosis after primary percutaneous coronary intervention
verfasst von
Alessandro Lupi
Gioel Gabrio Secco
Andrea Rognoni
Lidia Rossi
Maurizio Lazzero
Federico Nardi
Roberta Rolla
Giorgio Bellomo
Angelo Sante Bongo
Carlo Di Mario
Publikationsdatum
01.05.2012
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 4/2012
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-011-0628-z

Weitere Artikel der Ausgabe 4/2012

Journal of Thrombosis and Thrombolysis 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.